Carsten Hielscher

Stralsund, MV, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer.

Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: January 26, 2024

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.

Journal: BMC cancer

Published: January 26, 2024

Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.

Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.

Journal: Geburtshilfe und Frauenheilkunde

Published: January 10, 2024

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.

Journal: Geburtshilfe und Frauenheilkunde

Published: May 31, 2022

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 04, 2021

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 24, 2021

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".

Journal: Breast (Edinburgh, Scotland)

Published: January 08, 2021

Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.

Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 21, 2020

Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.

Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.

Journal: Geburtshilfe und Frauenheilkunde

Published: December 02, 2020

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.

Journal: Geburtshilfe und Frauenheilkunde

Published: October 03, 2020

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.

Journal: Cancers

Published: August 21, 2020

Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.

Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.

Journal: Future oncology (London, England)

Published: April 17, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026